Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidant's Ventak Prizm 2

This article was originally published in The Gray Sheet

Executive Summary

Dual-chamber ICD launches worldwide, firm announces Nov. 8. Automatic device is approximately 20% smaller than nearest competitor, Guidant notes. FDA approved the device via PMA supplement on Aug. 8 (1"The Gray Sheet" Aug. 14, 2000, p. 9). Separately, the firm's Multi-Link Pixel coronary stent receives a CE mark Nov. 7. Lesion-specific device is designed to treat first-time blockages in native coronary arteries and saphenous vein bypass grafts with diameters less than 3.0 mm. Guidant plans to apply for FDA approval of the system in the second half of 2001 following completion of 150-patient U.S. clinical trial. Also in the stent area, the company reports the launch of the 30-patient SSYLVIA trial for treatment of cerebral atherosclerosis

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel